What a 200% Tariff Actually Does to a $10 Bottle of Pills

THE TWO-YEAR CLOCK MATTERS MORE THAN THE

200% NUMBER A 200% tariff headline sounds like an immediate crisis for India's pharmaceutical exporters. It isn't, yet - and the reason it isn't is the actual story. The zero-tariff window runs until August 2028, which means the real question is not "can Indian pharma survive this tariff" but "what does India do with three years of advance notice."

Who Actually Absorbs the First Shock

Follow one shipment: a strip of Indian-made generic metformin, priced at roughly a tenth of its US branded equivalent. Even after a 100% tariff in 2028, that generic would likely still undercut the branded version - GTRI's own estimate is that Indian generics sell for seven to ten times less than branded alternatives.

So the first-round cost doesn't fall on Indian exporters losing the US market outright; it falls on the American healthcare system, which absorbs the markup through insurers, hospitals and out-of-pocket patient costs, because the US simply cannot replace 47% of its generic supply in three years.

Dr. Reddy's CEO Erez Israeli said as much directly: relocating operations that fast "is not practical." The pain, in the short run, lands in Ohio pharmacies before it lands in Hyderabad factories.

Where the Real Exposure Sits

The genuine risk for India isn't the tariff itself - it's what India does with the runway. Nearly 38% of India's pharma export revenue depends on one market and that concentration, not the tariff rate, is the structural vulnerability.

If Indian firms spend the next three years defending US market share instead of diversifying into the EU, Africa and Latin America or moving up the value chain into complex biosimilars where price competition matters less, the 2029 deadline arrives with India still holding the same exposure it has today - just with a much higher cost attached to keeping it.

Exports to the NAFTA region already fell 7.9% in 2025-26, which is either the beginning of that diversification or simply demand softening before the tariff even bites; which one it is will define whether India's pharmacy-of-the-world position survives this decade intact.

For UPSC, the exam-relevant insight is not "US imposed tariffs on Indian pharma"

• it is that this policy is a three-year stress test of whether India's generic-drug dominance rests on genuine cost competitiveness that survives any tariff or on market concentration that a single trading partner's policy shift can unwind.